Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Abstract Hematologic malignancies are one of the most common cancers, and the incidence has been rising in recent decades. The clinical and molecular features of hematologic malignancies are highly heterogenous, and some hematologic malignancies are incurable, challenging the treatment, and prognosi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-02-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-023-01342-6 |
| _version_ | 1797863422173380608 |
|---|---|
| author | Ailin Zhao Hui Zhou Jinrong Yang Meng Li Ting Niu |
| author_facet | Ailin Zhao Hui Zhou Jinrong Yang Meng Li Ting Niu |
| author_sort | Ailin Zhao |
| collection | DOAJ |
| description | Abstract Hematologic malignancies are one of the most common cancers, and the incidence has been rising in recent decades. The clinical and molecular features of hematologic malignancies are highly heterogenous, and some hematologic malignancies are incurable, challenging the treatment, and prognosis of the patients. However, hematopoiesis and oncogenesis of hematologic malignancies are profoundly affected by epigenetic regulation. Studies have found that methylation-related mutations, abnormal methylation profiles of DNA, and abnormal histone deacetylase expression are recurrent in leukemia and lymphoma. Furthermore, the hypomethylating agents and histone deacetylase inhibitors are effective to treat acute myeloid leukemia and T-cell lymphomas, indicating that epigenetic regulation is indispensable to hematologic oncogenesis. Epigenetic regulation mainly includes DNA modifications, histone modifications, and noncoding RNA-mediated targeting, and regulates various DNA-based processes. This review presents the role of writers, readers, and erasers of DNA methylation and histone methylation, and acetylation in hematologic malignancies. In addition, this review provides the influence of microRNAs and long noncoding RNAs on hematologic malignancies. Furthermore, the implication of epigenetic regulation in targeted treatment is discussed. This review comprehensively presents the change and function of each epigenetic regulator in normal and oncogenic hematopoiesis and provides innovative epigenetic-targeted treatment in clinical practice. |
| first_indexed | 2024-04-09T22:36:24Z |
| format | Article |
| id | doaj.art-b7990865ff6a4ff6916442fc33863a4f |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-04-09T22:36:24Z |
| publishDate | 2023-02-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-b7990865ff6a4ff6916442fc33863a4f2023-03-22T12:30:35ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352023-02-018114010.1038/s41392-023-01342-6Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignanciesAilin Zhao0Hui Zhou1Jinrong Yang2Meng Li3Ting Niu4Department of Hematology, West China Hospital, Sichuan UniversityDepartment of Hematology, West China Hospital, Sichuan UniversityDepartment of Hematology, West China Hospital, Sichuan UniversityDepartment of Hematology, West China Hospital, Sichuan UniversityDepartment of Hematology, West China Hospital, Sichuan UniversityAbstract Hematologic malignancies are one of the most common cancers, and the incidence has been rising in recent decades. The clinical and molecular features of hematologic malignancies are highly heterogenous, and some hematologic malignancies are incurable, challenging the treatment, and prognosis of the patients. However, hematopoiesis and oncogenesis of hematologic malignancies are profoundly affected by epigenetic regulation. Studies have found that methylation-related mutations, abnormal methylation profiles of DNA, and abnormal histone deacetylase expression are recurrent in leukemia and lymphoma. Furthermore, the hypomethylating agents and histone deacetylase inhibitors are effective to treat acute myeloid leukemia and T-cell lymphomas, indicating that epigenetic regulation is indispensable to hematologic oncogenesis. Epigenetic regulation mainly includes DNA modifications, histone modifications, and noncoding RNA-mediated targeting, and regulates various DNA-based processes. This review presents the role of writers, readers, and erasers of DNA methylation and histone methylation, and acetylation in hematologic malignancies. In addition, this review provides the influence of microRNAs and long noncoding RNAs on hematologic malignancies. Furthermore, the implication of epigenetic regulation in targeted treatment is discussed. This review comprehensively presents the change and function of each epigenetic regulator in normal and oncogenic hematopoiesis and provides innovative epigenetic-targeted treatment in clinical practice.https://doi.org/10.1038/s41392-023-01342-6 |
| spellingShingle | Ailin Zhao Hui Zhou Jinrong Yang Meng Li Ting Niu Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies Signal Transduction and Targeted Therapy |
| title | Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies |
| title_full | Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies |
| title_fullStr | Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies |
| title_full_unstemmed | Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies |
| title_short | Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies |
| title_sort | epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies |
| url | https://doi.org/10.1038/s41392-023-01342-6 |
| work_keys_str_mv | AT ailinzhao epigeneticregulationinhematopoiesisanditsimplicationsinthetargetedtherapyofhematologicmalignancies AT huizhou epigeneticregulationinhematopoiesisanditsimplicationsinthetargetedtherapyofhematologicmalignancies AT jinrongyang epigeneticregulationinhematopoiesisanditsimplicationsinthetargetedtherapyofhematologicmalignancies AT mengli epigeneticregulationinhematopoiesisanditsimplicationsinthetargetedtherapyofhematologicmalignancies AT tingniu epigeneticregulationinhematopoiesisanditsimplicationsinthetargetedtherapyofhematologicmalignancies |